Y. Chiu

Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders.

R. Findling, R. Goldman, A. Pikalov, 2015, Clinical therapeutics.

Lurasidone drug-drug interaction studies: a comprehensive review

S. Preskorn, L. Ereshefsky, A. Loebel, 2014, Drug metabolism and drug interactions.

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open‐label, crossover studies

S. Preskorn, L. Ereshefsky, A. Loebel, 2013, Human psychopharmacology.

Effect of age and gender on the pharmacokinetics of R667, a novel agent for the treatment of emphysema, in healthy volunteers.

S. Kolis, B. Brennan, Y. Chiu, 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study

S. Isaacson, P. Bhargava, Y. Chiu, 2021, Neurology and Therapy.

Human Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2 Cells

G. Amidon, L. Welage, J. Barnett, 2003, Pharmaceutical Research.

Pharmacokinetics of a novel agent, R667, in patients with emphysema.

M. Roth, B. Davies, S. Kolis, 2007, British journal of clinical pharmacology.

Pharmacokinetic Bioequivalence of Enfuvirtide Using a Needle‐Free Device versus Standard Needle Administration

I. Patel, R. Stout, A. True, 2006, Pharmacotherapy.

Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure: Results of a Pharmacokinetic Study of Enfuvirtide in HIV-1-Infected Patients With Impaired Kidney Function

P. Tebas, I. Patel, L. Rowell, 2008, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients

N. Graham, S. Walmsley, L. Rowell, 2008, HIV clinical trials.

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease

D. Blum, S. Chapel, Y. Chiu, 2021, Clinical and translational science.

Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.

J. Cucchiaro, A. Loebel, S. Chapel, 2016, Clinical therapeutics.

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects

G. D. Miralles, I. Patel, E. Dejesus, 2006, AIDS.